The firm, founded in 1996, focuses on disruptive scientific developments across multiple therapeutic areas including oncology, immunology, and neuroscience as well as emerging modalities of the cell, gene, and nucleic acid therapies. MPM Capital has a team of investment professionals, executive partners, entrepreneurs, and scientific advisory board members that help to power novel medical breakthroughs that transform patients' lives. They invest in seed, early, and later stage ventures, and private equity investments, and have nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. MPM Capital also has an affiliate, BioImpact Capital, which invests in impact and public equities products.